Cellectis to Share Q3 2024 Financial Results Soon
Cellectis, a leading clinical-stage biotechnology company, is preparing to announce its financial results for the third quarter of 2024. The report is set to be released after the market closes on November 4, 2024, marking an important milestone in their ongoing journey in gene editing and cell therapy development.
Conference Call Scheduled for Investors
Following the results announcement, Cellectis will hold an investor conference call on November 5, 2024. This event will start at 8:00 AM ET and will be an opportunity for attendees to learn more about the company's financial performance, along with an update on its current business activities and future prospects.
How to Join the Conference Call
Investors and interested parties can join the call using the following details:
Domestic Call: +1-800-225-9448
International Call: +1-203-518-9708
Conference ID: CLLSQ3
This conference call is an excellent opportunity for stakeholders to engage directly with Cellectis' leadership team and gain meaningful insights into the company's strategies and performance.
About Cellectis
Cellectis specializes in innovative gene-editing technologies. Its focus lies in developing groundbreaking cell and gene therapies to combat various diseases. With over 25 years of experience, Cellectis is paving the way for advanced CAR-T immunotherapies that utilize a unique allogeneic approach. This strategy features off-the-shelf, ready-to-use gene-edited CAR T-cells, making treatments more accessible for cancer patients globally.
Unique Technologies at the Forefront
The company leverages its proprietary TALEN® gene-editing technology, combined with its advanced PulseAgile electroporation system. These tools empower the creation of effective cell therapies, addressing significant unmet medical needs in healthcare.
Headquarters and Market Presence
Cellectis operates from its primary headquarters in Paris, France, with significant presences in New York and Raleigh, North Carolina. As a publicly traded entity listed on the Nasdaq Global Market as CLLS, Cellectis continues to make strides in the biopharmaceutical industry.
Company Contact Information
For more information about Cellectis' initiatives, please feel free to reach out to their communications team:
Media Contact: Pascalyne Wilson, Director, Communications, Phone: +33 (0)7 76 99 14 33, Email: media@cellectis.com
Investor Relations: Arthur Stril, Interim CFO, Phone: +1 (347) 809 5980, Email: investors@cellectis.com
Frequently Asked Questions
1. When will Cellectis announce its financial results?
Cellectis will announce its Q3 2024 financial results on November 4, 2024.
2. What can investors expect during the conference call?
Investors can expect updates on financial performance, business activities, and future strategies.
3. How can I participate in the conference call?
You can participate by dialing the domestic or international numbers provided, using the conference ID CLLSQ3.
4. What is the focus of Cellectis?
Cellectis focuses on developing innovative gene-editing therapies for cancer, utilizing groundbreaking technologies like TALEN®.
5. Where is Cellectis headquartered?
Cellectis is headquartered in Paris, France, with additional locations in New York and Raleigh, North Carolina.
